Transporter-Mediated Alterations in Patients With NASH Increase Systemic and Hepatic Exposure to an OATP and MRP2 Substrate

Effect of Liver Disease on Hepatic Transporter Expression and Function

(2017) Nilay Thakkar et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease

(2017) John D. Clarke et al.   LIVER INTERNATIONAL

The epidemiology of non-alcoholic fatty liver disease

(2017) Stefano Bellentani   LIVER INTERNATIONAL

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites

(2016) Mitesh Patel et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis

(2015) BC Ferslew et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

New insights in the biology of ABC transporters ABCC2 and ABCC3: impact on drug disposition

(2014) Lori WE van der Schoor et al.   Expert Opinion on Drug Metabolism & Toxicology

Synergistic interaction between genetics and disease on pravastatin disposition

(2014) John D. Clarke et al.   JOURNAL OF HEPATOLOGY

Increased Susceptibility to Methotrexate-Induced Toxicity in Nonalcoholic Steatohepatitis

(2014) Rhiannon N. Hardwick et al.   TOXICOLOGICAL SCIENCES

Liver transplantation and non-alcoholic fatty liver disease

(2014) Petros Zezos   WORLD JOURNAL OF GASTROENTEROLOGY

A Perspective on Efflux Transport Proteins in the Liver

(2012) K Köck et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy

(2012) R A Wilke et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability – considerations for drug development

(2012) Yurong Lai et al.   Expert Opinion on Drug Metabolism & Toxicology

The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

(2012) Naga Chalasani et al.   GASTROENTEROLOGY

Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus

(2012) Chirag G. Patel et al.   XENOBIOTICA

Variations in ATP-Binding Cassette Transporter Regulation during the Progression of Human Nonalcoholic Fatty Liver Disease

(2011) R. N. Hardwick et al.   DRUG METABOLISM AND DISPOSITION

Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States

(2011) Michael R. Charlton et al.   GASTROENTEROLOGY

Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake

(2011) M. Niemi et al.   PHARMACOLOGICAL REVIEWS

Transporters involved in the hepatic uptake of 99mTc-mebrofenin and indocyanine green

(2010) Wilmar de Graaf et al.   JOURNAL OF HEPATOLOGY

Evaluation of 99mTechnetium-Mebrofenin and 99mTechnetium-Sestamibi as Specific Probes for Hepatic Transport Protein Function in Rat and Human Hepatocytes

(2010) Brandon Swift et al.   PHARMACEUTICAL RESEARCH

Effects of Drug Transporters on Volume of Distribution

(2009) Anita Grover et al.   AAPS Journal

Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis

(2009) Etsuko Hashimoto et al.   JOURNAL OF GASTROENTEROLOGY

Adenosine Triphosphate-Binding Cassette Subfamily C Member 2 Is the Major Transporter of the Hepatobiliary Imaging Agent 99mTc-Mebrofenin

(2009) K. K. Bhargava et al.   JOURNAL OF NUCLEAR MEDICINE

Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans

(2008) T. Watanabe et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Use of Tc-99m Mebrofenin as a Clinical Probe to Assess Altered Hepatobiliary Transport: Integration of In Vitro, Pharmacokinetic Modeling, and Simulation Studies

(2008) Giulia Ghibellini et al.   PHARMACEUTICAL RESEARCH